You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
異動直擊 | 中醫藥板塊拉昇,同仁堂國藥漲近4%
uSMART盈立智投6月30日消息,同仁堂國藥漲近4%,報12.6元,同仁堂科技漲超3%,報7.21元,中國中藥漲超2%,報5.32元,白雲山漲超1%。
6月30日,國家衛健委、國家中醫藥局、中央軍委後勤保障部衛生局聯合發佈《關於進一步加強綜合醫院中醫藥工作推動中西醫協同發展的意見》。《意見》提出,衛生健康行政部門要將中西醫結合工作納入醫院評審和公立醫院績效考覈,推動綜合醫院中醫藥發展。設中醫臨牀科室(中醫科、中西醫結合科、民族醫學科,下同)的公立綜合醫院要把建立中西醫協同發展機制和多學科診療體系納入醫院章程,將中西醫聯合查房、會診納入醫院管理制度,結合中醫藥特點和規律,統籌優化並差別化實施中醫臨牀科室績效考覈,鼓勵和引導提供中醫藥服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.